Literature DB >> 23646046

Comparison of right and left side heart functions in patients with thalassemia major, patients with thalassemia intermedia, and control group.

Noormohammad Noori1, Mehdi Mohamadi, Kambiz Keshavarz, Seyed Mostafa Alavi, Maziar Mahjoubifard, Yalda Mirmesdagh.   

Abstract

BACKGROUND: Heart disease is the main cause of mortality and morbidity in patients with beta thalassemia, rendering its early diagnosis vital. We studied and compared echocardiographic findings in patients with beta thalassemia major, patients with beta thalassemia intermedia, and a control group.
METHODS: Eighty asymptomatic patients with thalassemia major and 22 asymptomatic cases with thalassemia intermedia (8-25 years old) were selected from those referred to Ali Asghar Hospital (Zahedan-Iran) between June 2008 and June 2009. Additionally, 80 healthy individuals within the same age and sex groups were used as controls. All the individuals underwent echocardiography, the data of which were analyzed with the Student t-test.
RESULTS: The mean value of the pre-ejection period/ejection time ratio of the left ventricle during systole, the diameter of the posterior wall of the left ventricle during diastole, the left and right isovolumic relaxation times, and the right myocardial performance index in the patients with beta thalassemia major and intermedia increased significantly compared to those of the controls, but the other parameters were similar between the two patient groups. The mean values of the left and right pre-ejection periods, left ventricular end systolic dimension, and left isovolumic contraction time in the patients with thalassemia intermedia increased significantly compared to those of the controls. In the left side, myocardial performance index, left ventricular mass index, isovolumic contraction time, and deceleration time exhibited significant changes between the patients with thalassemia major and those with thalassemia intermedia, whereas all the echocardiographic parameters of the right side were similar between these two groups.
CONCLUSION: The results showed that the systolic and diastolic functions of the right and left sides of the heart would be impaired in patients with thalassemia major and thalassemia intermedia. Consequently, serial echocardiography is suggested in asymptomatic patients with beta thalassemia for an early diagnosis of heart dysfunction and proper treatment.

Entities:  

Keywords:  Echocardiography; Heart diseases; Thalassemia

Year:  2013        PMID: 23646046      PMCID: PMC3587672     

Source DB:  PubMed          Journal:  J Tehran Heart Cent        ISSN: 1735-5370


Introduction

Thalassemia is the most common heterogeneous disease of the human being. It is a disease of high prevalence in Mediterranean, Indian, North Chinese, and Pacific populations. Every year, 100,000 neonates are born with hemoglobinopathies around the world. Recently, the quantity and quality of the life of these patients have been significantly improved by regular transfusion and iron chelating therapy.1 Heart disease is the main cause of mortality and morbidity in thalassemic patients. The two ends of the broad spectrum of the thalassemia range from asymptomatic carriers to patients with transfusion-related thalassemia major. A high cardiac output following chronic tissue hypoxia and increased pulmonary and systemic vascular resistance are the main factors which lead to heart disease in thalassemia intermedia. Pulmonary hypertension is an important manifestation of heart involvement and is specially presented by right-sided failure in patients with non-blood transfusion-related thalassemia intermedia. The cause of increased pulmonary vascular resistance in patients with beta thalassemia is multifactorial,2 and the main causes of early death among these patients are systolic and diastolic dysfunction following hemosiderosis. Increased iron re-absorption via the gastrointestinal system is the main cause of hemosiderosis rather than iron overload following blood transfusion.3 Research shows that end systolic volume (ESV) and end diastolic volume (EDV) tend to rise significantly in asymptomatic patients with thalassemia intermedia compared to controls.4 One study showed that iron overload had a major role in the progression of heart dysfunction in patients with beta thalassemia major, while a high cardiac output was the main causative factor in patients with thalassemia intermedia.5 Aessopos et al.6 reported bilateral ventricular dilatation and dysfunction in association with pulmonary hypertension as the major culprits for heart dysfunction in patients with sickle beta thalassemia. They also reported that heart disease was the major cause of death in patients with thalassemia and recommended echocardiography and cardiac magnetic resonance imaging (MRI) as useful tools in the early evaluation of cardiac involvement in those patients.7 Danish et al.8 suggested tissue Doppler imaging as a safe, simple, and repeatable method for patients with beta thalassemia major, not least in countries with a high incidence of thalassemia, compared to the MRI-T2 method. Our study compared echocardiographic variables in patients with thalassemia major, patients with thalassemia intermedia, and a control group.

Methods

This study is a case-control research and complies with the current ethical considerations. Informed consent was obtained from each patient included in the study, and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution’s Human Research Committee. Beta thalassemia major patients and cases with thalassemia intermedia were selected from patients who referred to Ali-Asghar Hospital in Zahedan University of Medical Sciences between June 2008 and June 2009. There are 1900 registered thalassemic patients in the south east of Iran. Of these patients,750 patients have registered records in the Center for Special Diseases of Ali-Asghar Hospital, Zahedan, Iran. In terms of age, 383 of these patients are older than 8 years. Among those 750 patients, there are only 30 cases with thalassemia intermedia, precluding a study on a larger number of patients with thalassemia intermedia. After history taking, physical examination, chest radiography, and electrocardiography (ECG), patients with mitral valve dysfunction, hypertension, structural diseases of the heart, heart failure, metabolic diseases, endocrine or renal disorders, pulmonary hypertension, cardiac drug consumption (except for chellators), hemoglobin before transfusion less than 9 g/dl, history of irregular transfusion before two years of age, and duration of chelating therapy less than 5 years were excluded from the study. Therefore, 8 patients with thalassemia intermedia were omitted: 2 patients with pulmonary hypertension; 4 patients less than 8 years old; and 2 patients over 25 years of age. Finally, 80 patients with thalassemia major and 22 patients with thalassemia intermedia (hemoglobin > 9g/dl in both groups) were recruited into the study. The age of the patients was between 8 and 25 years old. After the registration of the patients’ age, sex, and blood pressure, the whole study population underwent two-dimensional and Doppler echocardiography by one cardiologist, using the Challenge 7000 Instrument with 2.5, 3.5, and 5-MHz transducers (made in Italy). This device was equipped with ECG monitoring. In addition, 80 healthy individuals, between 8 and 25 years of age, who referred for routine examination or follow-up, were chosen and matched for sex with the case groups as controls. The means of all necessary echocardiographic parameters, namely posterior wall dimension in systole (PWDS) and posterior wall dimension in diastole (PWDD) of the left side, acceleration time (AT), deceleration time (DT), myocardial performance index (MPI), peak E (early mitral valve flow velocity)/peak A (late mitral valve flow velocity) velocity (E/A ratio), isovolumic relaxation time (IRT), isovolumic contraction time (ICT) of both sides, ejection fraction (EF), fractional shortening (FS), interventricular septal dimension in diastole (IVSDD), interventricular septal dimension in systole (IVSDS), left ventricular end-diastolic dimension (LVDD), and left ventricular end-systolic dimension (LVSD) of the left side, were measured in each of the three cardiac cycles. Additionally, posterior wall dimension in systole of the left ventricle (LVPWS), posterior wall dimension in diastole of the left ventricle (LVPWD), interventricular septal dimension in systole (IVSS), EF, and FS were measured via M-mode echocardiography. Also, the velocity of the blood flow through the heart valves was measured with pulsed Doppler, and the pre-ejection time, ejection time (ET), peak A velocity (A), peak E velocity (E), E/A ratio, and pre-ejection period/ejection time ratio (PEP/ET) of both sides were measured with pulsed Doppler echocardiography.9 The sample volume was positioned at the tips of the tricuspid and mitral valve leaflets in the apical four-chamber view to enable the measurement of (a), which is the time of interval between the end and the start of trans-mitral and trans-tricuspid flow. The sample volume was thereafter relocated to the left ventricular outflow tract just below the aortic valve (apical five-chamber view) so as to measure (b), which is the left ventricular ejection time. The right ventricular outflow velocity pattern was also recorded from the parasternal short-axis view with the Doppler sample volume positioned just distal to the pulmonary valve for the measurement of (b). MPI or the Tie Index was calculated as: a-b/b = IRT + ICT/ET.9 The left ventricular mass index (LVMI) was also calculated by the following formula: 10 All the parameters in the above formula were measured in the M-mode view and in diastole and were utilized for left ventricular mass evaluation. Finally, the a statistical method for making simultaneous comparisons between two or more means (ANOVA) was employed for the normally distributed variables and the Kruskal-Wallis test was used for the non-normally distributed variables. Multiple comparisons between the groups were performed with the Tukey test. A p value < 0.05 was considered statistically significant.

Results

Eighty patients with beta thalassemia major and 22 patients with thalassemia intermedia, between 8 and 25 years old, as well as 80 healthy individuals within the same age range were recruited in this study. There was no significant difference in terms of the mean age between the three groups (p value = 0.875); however, the other demographic parameters (Table 1) were significantly different between the studied groups. The most remarkable of these factors was systolic blood pressure, which exhibited a significant difference between all the groups (p value < 0.001).
Table 1

Demographic parameters in the patients with thalassemia major, patients with thalassemia intermedia, and controls

ParametersGroupsMeanStandard DeviationP valueTukey testP value
Age (y)Major16.262.980.875vs. Intermedia0.956
Intermedia16.505.82vs. Control0.937
Control16.072.98vs. Major0.865
Height (cm)Major146.719.48< 0.001vs. Intermedia0.011
Intermedia137.8717.86vs. Control0.010
Control152.6013.52vs. Major< 0.001
Weight (kg)Major36.606.960.012vs. Intermedia0.922
Intermedia35.6511.36vs. Control< 0.001
Control54.015.84vs. Major< 0.001
Hemoglobin (g/dl)Major10.231.08< 0.001vs. ntermedia0.952
Intermedia10.160.88vs. Control< 0.001
Control14.630.84vs. Major< 0.001
Systolic BP (mm Hg)Major90.317.80< 0.001vs. Intermedia0.223
Intermedia96.9510.08vs. Control< 0.001
Control100.5823.16vs. Major< 0.001
Diastolic BP (mm Hg)Major64.315.72< 0.001vs. Intermedia0.001
Intermedia70.907.50vs. Control< 0.884
Control70.186.57vs. Major< 0.001

BP, Blood pressure

Based on Table 2 and Table 3, depicting the echocardiographic parameters of the left heart, the mean interventricular septum diameter in diastole and the mean posterior ventricular wall diameter in diastole were significantly increased in both of the patient groups compared to those in the controls (p value = 0.018 and p value = 0.018, respectively). In both of the thalassemia groups, the mean left IRT was significantly higher than that of the healthy controls (p value < 0.001).
Table 2

Echocardiographic parameters of the left heart in the patients with thalassemia major, patients with thalassemia intermedia, and controls

ParametersGroupsMeanStandard deviationP valueTukey testP value
MPIMajor0.600.130.001vs. Intermedia< 0.001
Intermedia0.640.12vs. Control< 0.001
Control0.520.08vs. Major< 0.001
LVMI (g/m2)Major86.6529.980.001vs. Intermedia0.002
Intermedia110.0540.86vs. Control0.065
Control76.5322.06vs. Major< 0.001
PEP (ms)Major98.6910.870.001vs. Intermedia0.072
Intermedia936.319.40vs. Control0.443
Control90.359.46vs. Major< 0.001
ET (ms)Major256.9526.270.113vs. Intermedia0.533
Intermedia250.8025.45vs. Control0.367
Control262.0720.70vs. Major0.125
PEP/ETMajor0.380.060.001vs. Intermedia0.576
Intermedia0.360.03vs. Control< 0.001
Control0.340.04vs. Major0.064
IVSD (mm)Major6.941.440.018vs. Intermedia0.328
Intermedia7.391.76vs. Control0.046
Control6.441.02vs. Major0.009
LVPWD (mm)Major4.431.100.018vs. Intermedia0.700
Intermedia4.611.40vs. Control0.010
Control3.990.49vs. Major0.018
IVSS (mm)Major10.201.820.033vs. Intermedia0.242
Intermedia10.872.52vs. Control0.383
Control9.841.32vs. Major0.037
LVPWS (mm)Major4.461.220.274vs. Intermedia0.539
Intermedia4.721.50vs. Control0.103
Control4.130.48vs. Major0.045
LVEDD (mm)Major47.644.840.790vs. Intermedia0.704
Intermedia48.726.93vs. Control0.730
Control48.315.98vs. Major0.951
LVESD (mm)Major32.624.090.426vs. Intermedia0.827
Intermedia31.785.36vs. Control0.940
Control32.937.42vs. Major0.699

MPI, Myocardial performance index; LVMI, Left ventricular mass index; PEP, Pre-ejection period; ET, Ejection time; PEP/ET, Pre-ejection period/ejection time ratio; IVSD, Interventricular septal dimension in diastole; LVPWD, Left ventricular posterior wall dimension in diastole; IVSS, Interventricular septal dimension in systole; LVPWS, Left ventricular posterior wall dimension in systole; LVEDD, Left ventricular end – diastolic dimension; LVESD, Left ventricular end- systolic dimension

Table 3

Echocardiographic parameters of the left heart in the patients with thalassemia major, patients with thalassemia intermedia, and controls

ParametersGroupsMeanStandard DeviationP valueTukey testP value
EF (%)Major59.126.570.001vs. Intermedia0.277
Intermedia61.597.12vs. Control0.001
Control65.466.63vs. Major0.044
FS (%)Major31.514.770.001vs. Intermedia0.161
Intermedia33.685.26vs. Control< 0.001
Control36.174.94vs. Major0.091
Diameter Ao (mm)Major23.423.080.543vs. Intermedia0.221
Intermedia24.264.08vs. Control0.996
Control23.632.95vs. Major0.200
Diameter LA (mm)Major27.933.690.203vs. Intermedia0.512
Intermedia29.453.81vs. Control0.906
Control27.893.81vs. Major0.680
LA/AoMajor1.200.180.454vs. Intermedia0.913
Intermedia1.220.17vs. Control0.662
Control1.180.17vs. Major0.593
ICT (ms)Major30.0415.460.001vs. Intermedia< 0.001
Intermedia43.6818.78vs. Control0.635
Control28.0011.10vs. Major< 0.001
IRT (ms)Major108.6723.290.001vs. Intermedia0.950
Intermedia110.0916.49vs. Control< 0.001
Control96.3215.26vs. Major0.010
AT (ms)Major72.7525.310.583vs. Intermedia0.089
Intermedia61.8616.33vs. Control0.284
Control78.1720.18vs. Major0.504
DT (ms)Major114.1119.130.001vs. Intermedia0.024
Intermedia126.0918.78vs. Control< 0.001
Control125.3718.59vs. Major0.986
E/AMajor2.042.080.415vs. Intermedia0.094
Intermedia1.590.23vs. Control0.345
Control1.920.50vs. Major0.008

EF, Ejection fraction; FS, Fractional shortening; Ao, Aorta; LA, Left atrium; LA/Ao, Left atrium/aorta ratio; ICT, Isovolumic contraction time; IRT, Isovolumic relaxation time; AT, Acceleration time; DT, Deceleration time; E /A ratio, peak E (early mitral valve flow velocity)/peak A (late mitral valve flow velocity) ratio

In the left side, MPI, left ventricular myocardial index (LVMI), ICT, and DT were statistically different between the patients with major thalassemia and those with thalassemia intermedia (p value < 0.001 for all the parameters), while the other parameters of the left side were similar between the two patient groups (Tables 2 and 3). In the thalassemia major group, the mean DT was significantly less than that of the other groups (p value < 0.001). Comparisons of the other parameters between the study groups are presented in Tables 2 and 3. Based on the echocardiographic parameters of the right heart (Table 4), the mean MPI and IRT were significantly different between the patient groups and the control group (p value < 0.001, p value < 0.001, respectively). These parameters were higher in the patients with thalassemia intermedia than in the other groups. The mean PEP/ET ratio and the right ventricular PEP increased significantly in the patients with thalassemia major compared to the controls (p value < 0.001). The mean ET and AT did not show significant differences between the study groups. Overall, no significant differences could be detected between the two patient groups on the basis of the right echocardiographic parameters.
Table 4

Echocardiographic parameters of the right heart in the patients with thalassemia major, patients with thalassemia intermedia, and controls

ParametersGroupsMeanStandard DeviationP valueTukey testP value
MPIMajor0.520.120.001vs. Intermedia0.333
Intermedia0.620.13vs. Control< 0.001
Control0.400.06vs. Major< 0.001
PEP (ms)Major96.0810.150.013vs. Intermedia0.196
Intermedia92.1011.62vs. Control0.013
Control91.788.18vs. Major0.989
ET (ms)Major259.8627.030.374vs. Intermedia0.407
Intermedia251.9029.81vs. Control0.991
Control260.3723.17vs. Major0.362
PEP/ETMajor0.360.050.015vs. Intermedia0.953
Intermedia0.360.06vs. Control0.013
Control0.340.03vs. Major0.255
ICT (ms)Major32.7017.110.234vs. Intermedia0.333
Intermedia38.4420.89vs. Control0.360
Control36.3315.12vs. Major0.861
IRT (ms)Major125.9623.090.001vs. Intermedia0.496
Intermedia131.1320.92vs. Control< 0.001
Control107.0212.97vs. Major< 0.001
AT (ms)Major73.2025.210.636vs. Intermedia0.510
Intermedia67.6823.04vs. Control0.185
Control67.4313.84vs. Major0.999
DT (ms)Major111.7127.100.001vs. Intermedia0.051
Intermedia125.8626.04vs. Control0.001
Control134.5522.19vs. Major0.319
E/AMajor1.230.320.001vs. Intermedia0.441
Intermedia1.330.37vs. Control< 0.001
Control1.510.33vs. Major0.063

MPI, Myocardial performance index; PEP, Pre-ejection period; ET, Ejection time; PEP/ET, Pre-ejection period/ejection time ratio; ICT, Isovolumic contraction time; IRT, Isovolumic relaxation time; AT, Acceleration time; DT, Deceleration time; E /A ratio, peak E (early mitral valve flow velocity)/peak A (late mitral valve flow velocity) ratio

Discussion

The major causes of morbidity and mortality in beta thalassemic patients are cardiomyopathy and finally heart failure. Dilated cardiomyopathy leads to ventricular dilatation and impaired contraction. Restrictive cardiomyopathy interferes with left ventricular filling, which finally gives rise to pulmonary hypertension and right heart failure. Myocardial iron deposition and immuno-inflammatory processes are known as important causes of cardiac involvement in such patients.11 In this study, the mean age and mean sex were not significantly different between the three study groups, whereas the mean weight and mean height were different significantly, which is similar to the results of the Bosi et al.,12 Aessopos et al.,13 and Karimi et al. studies.14 The mean hemoglobin and mean hematocrit were significantly different between the patient groups and the control group; however, these parameters were similar between the two thalassemic groups. Other investigations have shown similar results.4, 12, 13 Decreases in systolic and diastolic blood pressures were significant in our two patient groups compared to the control group; these results chime in with the findings of the Bosi et al.,12 and Vaccari studies,15 which reported that stroke volume, cardiac output, left ventricular end systolic dimension and left ventricular end diastolic dimension volumes, and left ventricular mass would increase in thalassemic patients with no symptoms of cardiac involvement. All such findings have also been reported by a large number of investigators. Stakos et al.16 reported that systolic and diastolic blood pressures were not different in thalassemic patients with no iron deposition in the cardiac tissue (measured via MRI) compared to healthy individuals. They also revealed iron overload in the heart tissue as the main cause of the drop in blood pressure in patients with thalassemia. There is also some evidence supporting increased left ventricular mass and aortic wall thickening in asymptomatic patients, caused by iron overload and iron deposition in the cardiac tissue. Patients with beta thalassemia major even in younger ages reveal diastolic and less often systolic dysfunction. These problems progress in older ages. Our study demonstrated that in the patients under 10 years old and also in those over than 10 years of age, MPI increased in the right and left ventricles. Nevertheless, tissue Doppler imaging also had an increase in the patients over 10 years old. Left PEP/ET showed no significant difference between both thalassemic groups, whereas the condition was not the same in the right side. Early diastolic involvement, especially in the right side, causes increased PEP/ET. During life, in asymptomatic thalassemic patients with cardiac involvement, DT gradually reduces. As a result, decreased DT is known as an important predictive parameter in the early diagnosis of cardiac involvement.9, 17, 18 Ocal et al.19 reported that the mean left MPI significantly increased in the patients with thalassemia treated with Doxorubicin compared to a control group. They also demonstrated that increased IRT and decreased ET without any change in ICT were the main causes of increasing MPI. In the present study, the mean ICT showed significant differences between the two patient groups. Increase in MPI is drawn upon as a sign of the coincidence of systolic and diastolic dysfunction. An increase in IRT (an index for diastolic function) is a marker of relaxation impairment due to iron deposition, which gradually leads to restrictive cardiomyopathy. Restrictive cardiomyopathy is known as the earliest sign of left ventricular diastolic dysfunction.15, 20, 21 As the Hahalis and colleagues study22 showed, right ventricular filling disorder in patients with thalassemia major is caused by increased IRT, even though in the left side, increased preload is known as the main cause of filling disorder. Decreased DT in the tricuspid valve has been used as a good predictor of cardiac dysfunction. These data are similar to our findings. In the current study, LVMI, an effective factor in ventricular compliance, increased significantly and it was deemed the cause of diastolic dysfunction in the patients with thalassemia. An increase in LVMI has been also reported by Bosi et al.,12 Kucuk et al.,23 and Noori.24 An increase in the ventricular mass was also shown in the Aldouris study.25 An increase in the PEP/ET ratio in the patients with thalassemia major and those with thalassemia intermedia compared to the ratio in the controls demonstrated early changes in the ventricular diastolic function. This was similar to the results of Hahalis et al.,15 Bosi et al.,12 and Vaccari et al.,22 who described similar reductions in the EF and FS in patients with thalassemia compared to the controls. Decreased DT is the best predictive value in patients with thalassemia and it is also the most important factor in the prognosis of such patients.26 Based on our research, the E/A ratio showed a decrease in the thalassemic patients compared to the controls. Iarassi21 also described similar results. Interventricular septal dimension during systole and diastole as well as LVPWS increased significantly in our thalassemic patients compared to our controls. These results are different from those in the Karimi study,14 but similar to the ones in the Stakos et al. study.16 The study of Ismaeel et al.27 showed that the evaluation of the right ventricular performance would be beneficial in future studies in order to localize the pathology in intermedia thalassemic patients with cardiomyopathy. Amoozegar28 reported that pulsed Doppler and pulsed tissue Doppler imaging were more sensitive than M-mode and two-dimensional echocardiography in beta thalassemic and intermedia patients, and Bilge et al.29 argued that tissue Doppler imaging assessment by echocardiography was more useful in the early detection of left ventricular dysfunction than conventional echocardiography.

Conclusion

Our study revealed that despite a disruption in the left and right diastolic functions in the patients with thalassemia major and intermedia, only some of the echocardiographic parameters of the left side changed significantly, whereas all the echocardiographic parameters of the right side remained without significant differences. A good knowledge of these differences would help us better evaluate patients with thalassemia major and intermedia with a view to an early detection of cardiac involvement and early commencement of treatment before the progression of the disease. Serial echocardiography is, therefore, recommended for an early detection of cardiac dysfunction even in asymptomatic patients with thalassemia major and intermedia.
  26 in total

1.  Left ventricular remodeling, systolic function, and diastolic function in young adults with beta-thalassemia intermedia: a Doppler echocardiography study.

Authors:  Marco Vaccari; Roberto Crepaz; Monica Fortini; Maria R Gamberini; Sabrina Scarcia; Walter Pitscheider; Giuliano Bosi
Journal:  Chest       Date:  2002-02       Impact factor: 9.410

2.  Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia.

Authors:  Mehran Karimi; Mohammad Borzouee; Alireza Mehrabani; Nader Cohan
Journal:  Eur J Haematol       Date:  2008-12-05       Impact factor: 2.997

3.  Cardiac and pulmonary dysfunction in asymptomatic beta-thalassanemia major.

Authors:  Noor Mohammad Noori; Kambiz Keshavarz; Mosaeib Shahriar
Journal:  Asian Cardiovasc Thorac Ann       Date:  2012-10

4.  Echocardiographic evaluation of systolic and diastolic heart function in patients suffering from beta-thalassemia major aged 5-10 years at the Zahedan Research Center for Children and Adolescent Health.

Authors:  Noor Mohammad Noori; Semira Mehralizadeh
Journal:  Anadolu Kardiyol Derg       Date:  2010-04

5.  Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia.

Authors:  Athanasios Aessopos; Dimitrios Farmakis; Spyros Deftereos; Maria Tsironi; Stergios Tassiopoulos; Ioannis Moyssakis; Markisia Karagiorga
Journal:  Chest       Date:  2005-05       Impact factor: 9.410

6.  Evaluation of cardiac functions in patients with thalassemia major.

Authors:  N O Küçük; G Aras; T Sipahi; E Ibiş; N Akar; A Soylu; G Erbay
Journal:  Ann Nucl Med       Date:  1999-06       Impact factor: 2.668

7.  Cardiac involvement in thalassemia intermedia: a multicenter study.

Authors:  A Aessopos; D Farmakis; M Karagiorga; E Voskaridou; A Loutradi; A Hatziliami; J Joussef; J Rombos; D Loukopoulos
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

8.  High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation.

Authors:  M A Aldouri; B Wonke; A V Hoffbrand; D M Flynn; S E Ward; J E Agnew; A J Hilson
Journal:  Acta Haematol       Date:  1990       Impact factor: 2.195

9.  Early echocardiographic findings in β-thalassemia intermedia patients using standard and tissue Doppler methods.

Authors:  Hamid Amoozgar; Nahal Farhani; Mehran Karimi
Journal:  Pediatr Cardiol       Date:  2010-11-17       Impact factor: 1.655

Review 10.  Heart disease in thalassemia intermedia: a review of the underlying pathophysiology.

Authors:  Athanasios Aessopos; Maria Kati; Dimitrios Farmakis
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

View more
  10 in total

1.  Left Ventricular Regional Function in Children with Beta Thalassemia with No Cardiac Manifestations (Four-Dimensional Echocardiographic Study).

Authors:  Osama Abdrabelrasool El Razaky; Mohamed Ramadan El-Shanshory; Waleed Ahmed El-Shehaby; Nahed Mohamed Hables; Adel Mohamed Elshamia; Ahmed Mohamed Fayed; Ahmed Elsayed El-Kholy; Esraa Ahmed El-Dosoky
Journal:  Indian J Hematol Blood Transfus       Date:  2019-03-22       Impact factor: 0.900

2.  The Correlation between Troponin and Ferritin Serum Levels in the Patients with Major Beta-Thalassemia.

Authors:  Iraj Shahramian; Motahhare Razzaghian; Abbas Ali Ramazani; Ghasem Ali Ahmadi; Noor Mohammad Noori; Ali Reza Rezaee
Journal:  Int Cardiovasc Res J       Date:  2013-06-01

3.  Is the diagnostic value of electrocardiography for the measurement of left ventricular mass index underestimated? Reply.

Authors:  Noor Mohammad Noori; Maziar Mahjoubifard
Journal:  J Tehran Heart Cent       Date:  2014

4.  Comparison between brain natriuretic peptide and calcitonin gene-related peptide in children with dilated cardiomyopathy and controls.

Authors:  Noor Mohammad Noori; Alireza Teimouri; Iraj Shahramian
Journal:  Niger Med J       Date:  2017 Jan-Feb

5.  Global Globin Network Consensus Paper: Classification and Stratified Roadmaps for Improved Thalassaemia Care and Prevention in 32 Countries.

Authors:  Bin Hashim Halim-Fikri; Carsten W Lederer; Atif Amin Baig; Siti Nor Assyuhada Mat-Ghani; Sharifah-Nany Rahayu-Karmilla Syed-Hassan; Wardah Yusof; Diana Abdul Rashid; Nurul Fatihah Azman; Suthat Fucharoen; Ramdan Panigoro; Catherine Lynn T Silao; Vip Viprakasit; Norunaluwar Jalil; Norafiza Mohd Yasin; Rosnah Bahar; Veena Selvaratnam; Norsarwany Mohamad; Nik Norliza Nik Hassan; Ezalia Esa; Amanda Krause; Helen Robinson; Julia Hasler; Coralea Stephanou; Raja-Zahratul-Azma Raja-Sabudin; Jacques Elion; Ghada El-Kamah; Domenico Coviello; Narazah Yusoff; Zarina Abdul Latiff; Chris Arnold; John Burn; Petros Kountouris; Marina Kleanthous; Raj Ramesar; Bin Alwi Zilfalil
Journal:  J Pers Med       Date:  2022-03-31

6.  The Correlation between Serum Level of Leptin and Troponin in Children with Major Beta-Thalassemia.

Authors:  I Shahramian; N M Noori; A Teimouri; E Akhlaghi; E Sharafi
Journal:  Iran J Ped Hematol Oncol       Date:  2015-03-15

7.  A study of leptin serum concentrations in patients with major Beta-thalassemia.

Authors:  I Shahramian; E Akhlaghi; A Ramezani; A Rezaee; N Noori; E Sharafi
Journal:  Iran J Ped Hematol Oncol       Date:  2013-04-22

8.  Correlation between serum leptin level and thyroid hormones in children with major beta-thalassemia .

Authors:  I Shahramian; Nm Noori; Aa Ramezani; E Sharafi; E Akhlaghi
Journal:  Iran J Ped Hematol Oncol       Date:  2013-10-22

9.  Comparison of QT Dispersion With Left Ventricular Mass Index in Early Diagnosis of Cardiac Dysfunction in Patients With β-Thalassemia Major.

Authors:  Noor Mohammad Noori; Maziar Mahjoubifard; Mehdi Mohammadi; Alireza Jahangiri Fard; Abdolhossein Abassi; Behrooz Farzanegan
Journal:  Iran Red Crescent Med J       Date:  2014-05-05       Impact factor: 0.611

10.  Echocardiographic evaluation of thalassemia intermedia patients in Duhok, Iraq.

Authors:  Ameen Mosa Mohammad
Journal:  BMC Cardiovasc Disord       Date:  2014-12-11       Impact factor: 2.298

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.